title: Lymphocytotoxic crossmatch in pediatric living donor liver transplantation.
abstract: To investigate the relationship between the pretransplant LCT results and the outcome after pediatric LDLT in a single center. The clinical data of 76 children undergoing 79 LDLTs including three retransplantations from May 2001 to January 2006 were retrospectively analyzed. All of the children had end-stage liver disease, and their median age was 1.4 yr (range, six months to 16.5 yr). Immunosuppressive therapy consisted of cyclosporine- or FK-based regimens with steroids. The children were classified into two groups (positive or negative) according to the pretransplant LCT results. The incidences of post-transplant surgical complications and of rejection episodes were compared. The relationship between the pretransplant LCT results and patient and graft survival rates was also analyzed. Seventy-nine pretransplant crossmatch tests were done; 13 (16.5%) were positive, and 66 (83.5%) were negative. No significant difference was found in the pretransplant clinical factors between two crossmatch groups. There was no significant difference between the groups in the incidence of vascular and biliary tract complications, in the rate of early or steroid-resistant cellular rejections, or in one- and three-yr patient (91.7%, 91.7%, respectively, in the positive group, 93.5%, 93.5%, respectively, in the negative group, p = 0.80) and graft (92.3%, 92.3%, respectively, in the positive group, 88.8%, 86.4%, respectively, in the negative group, p = 0.63) survival. The present study demonstrates that there is no reason to do pretransplant LCT to select the living donor for pediatric LDLT.
authors.affiliation: Division of Transplant Surgery, Jichi Medical University, Tochigi, Japan. takk@faculty.chiba-u.jp
authors.forename: Takeshi
authors.initials: T
authors.lastname: Saito
authors.forename: Koichi
authors.initials: K
authors.lastname: Mizuta
authors.forename: Shuji
authors.initials: S
authors.lastname: Hishikawa
authors.forename: Youichi
authors.initials: Y
authors.lastname: Kawano
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Sanada
authors.forename: Takehito
authors.initials: T
authors.lastname: Fujiwara
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Yasuda
authors.forename: Koichi
authors.initials: K
authors.lastname: Sugimoto
authors.forename: Koichi
authors.initials: K
authors.lastname: Sakamoto
authors.forename: Hideo
authors.initials: H
authors.lastname: Kawarasaki
mesh_terms: D000293:Adolescent; D000917:Antibody Formation; D002648:Child; D002675:Child, Preschool; D005260:Female; D006084:Graft Rejection; D006085:Graft Survival; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D007223:Infant; D008107:Liver Diseases / Q000601:surgery / Q000628:therapy*; D016031:Liver Transplantation / Q000379:methods*; D019520:Living Donors; D008297:Male; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014019:Tissue Donors; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents